Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HPGDS | O60760 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483056 | 1.00 | ALDH1A1 (0.47) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL28152219 | 0.96 | ALDH1A1 (0.43) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL15773400 | 0.96 | ALDH1A1 (0.43) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL12139802 | 0.88 | HPGDS (0.51) | ALDH1A1TSHRHPGDSHSD17B10NR1I2 | |
| SCHEMBL18526617 | 0.86 | ALDH1A1 (0.45) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL47078 | 0.86 | ALDH1A1 (0.45) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL18057081 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL2711186 | 0.85 | UCHL1 (0.44) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL19225799 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL18829237 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| WO-2011060000-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060000-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059850-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010111534-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065668-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TSHR 4635/4885KMT2A 4516/4885 |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885TSHR 4860/4885KMT2A 4294/4885 |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885TSHR 4860/4885KMT2A 4294/4885 |
| US-10807990-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885TSHR 4860/4885KMT2A 4294/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 3957/4885TSHR 4853/4885KMT2A 3803/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885TSHR 4860/4885KMT2A 4294/4885 |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885TSHR 4860/4885KMT2A 4294/4885 |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885TSHR 4860/4885KMT2A 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.